Replies to post #376815 on Amarin Corp Plc (AMRN)

[Number sleven]

Raf, Thanks for the numbers.
Sleven,

[Jasbg]

raf, Thanks as always.

Numbers don't lie - and these numbers are in line with what we just witnessed after Q1 presentation.

Generics have past 50% of Amarin sales.

We need help ASAP - BP to take over marketing - sales and organisation - for this great drug to ever reach the millions of CDV patients out there WW.

[iryokabu]

Thank you, Raf!

[Megc]

Thanks Raf, appreciate the scripts.

[rafunrafun]

Scripts for week ending May 6, 2022

Drug Industry TRx: +0.8% w/w; +8.5% y/y

Vascepa
TRx 66,697; -0.4% (-294) w/w; -21.9% y/y
NRx 30,685; -1.8% (-578) w/w; -20.2% y/y
Ref 36,012; +0.8% (+284) w/w; -23.3% y/y

Lovaza (Generic & Brand)
TRx 63,121; -0.9% (-541) w/w; -0.9% y/y
NRx 31,643; -0.5% (-146) w/w; +2.5% y/y
Ref 31,477; -1.2% (-395) w/w; -4.0% y/y

Generic Vascepa
TRx 36,229; +0.3% (+119) w/w; As % of total V: 35.2%
NRx 20,414; -1.6% (-340) w/w; As % of total V: 39.9%
Ref 15,815; +3.0% (+458) w/w; As % of total V: 30.5%

Generic Vascepa by Manufacturer
Hikma - TRx 8,366; (+958) w/w; Generic share 23.1%; Total V share 8.1%
Reddy - TRx 17,992; (-574) w/w; Generic share 49.7%; Total V share 17.5%
Apotex - TRx 9,871; (-265) w/w; Generic share 27.2%; Total V share 9.6%

Vascepa + Generic Vascepa
TRx 102,927; -0.2% (-176) w/w; +7.9% y/y
NRx 51,099; -1.8% (-917) w/w; +15.9% y/y
Ref 51,827; +1.5% (+742) w/w; +0.9% y/y